Vasoregulatory peptides pro-endothelin-1 and pro-adrenomedullin are associated with metabolic syndrome in the population-based KORA F4 study

European Journal of Endocrinology

Volumn 167, Issue 6, 2012, Pages 847-853

  Seissler, Jochen ^a,b   Feghelm, Nina ^a   Then, Cornelia ^a   Meisinger, Christa ^c   Herder, Christian ^d   Koenig, Wolfgang ^e   Peters, Annette ^c   Roden, Michael ^d,f   Lechner, Andreas ^a,b   Kowall, Bernd ^d   Rathmann, Wolfgang ^d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e UNIVERSITY OF ULM   (Germany)

^f UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CARBOXY TERMINAL PROENDOTHELIN 1; CREATININE; PROADRENOMEDULLIN; PROENDOTHELIN 1; PROTEIN PRECURSOR; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; FEMALE; HUMAN; INSULIN RESISTANCE; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SEX DIFFERENCE; VASCULAR DISEASE;

ADRENOMEDULLIN; ADULT; AGED; ENDOTHELIN-1; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PEPTIDE FRAGMENTS;

EID: 84869040131     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0472     Document Type: Article

References (37)

1. Zimmet P, Magliano D, Matsuzawa Y, Alberti G & Shaw J. The metabolic syndrome: a global public health problem and a new definition. Journal of Atherosclerosis and Thrombosis 2005 12 295-300. (doi:10.5551/jat.12.295)
2. Clough G, Krentz AJ & Byrne CD. Vascular disease in the metabolic syndrome: do we need to target the microcirculation to treat large vessel disease? Journal of Vascular Research 2009 46 515-526. (doi:10.1159/000176041)
3. Tesauro M & Cardillo C. Obesity, blood vessels and metabolic syndrome. Acta Physiologica 2011 203 279-286. (doi:10.1111/j.1748-1716.2011. 02290.x)
4. Thorin E & Webb DJ. Endothelium-derived endothelin-1. Pflügers Archiv: European Journal of Physiology 2010 459 951-958. (doi:10.1007/s00424- 009-0763-y)
5. Ottosson-Seeberger A, Lundberg JM, Alvestrand A & Ahlborg G. Exogenous endothelin-1 causes peripheral insulin resistance in healthy humans. Acta Physiologica Scandinavica 1997 161 211-220. (doi:10.1046/j.1365-201X.1997. 00212.x)
6. Lee YC, Juan CC, Fang VS, Hsu YP, Lin SH, Kwok CF & Ho LT. Evidence that endothelin-1 (ET-1) inhibits insulin-stimulated glucose uptake in rat adipocytes mainly through ETA receptors. Metabolism 1998 47 1468-1471. (doi:10.1016/S0026-0495 (98)90071-3)
7. DeLoach S, Huan Y, Daskalakis C & Falkner B. Endothelin-1 response to glucose and insulin among African Americans. Journal of the American Society of Hypertension 2010 4 227-235. (doi:10.1016/j.jash.2010.07.004)
8. Ak G, Buyukberber S, Sevinc A, Turk HM, Ates M, Sari R, Savli H & Cigli A. The relation between plasma endothelin-1 levels and metabolic control, risk factors, treatment modalities, and diabetic microangiopathy in patients with type 2 diabetes mellitus. Journal of Diabetes and its Complications 2001 5 150-157. (doi:10.1016/S1056-8727(01)00137-4)
9. Behnes M, Papassotiriou J, Walter T, Fiedler E, Sauer T, Lang S, Elmas E, Hoffmann U, Borggrefe M & Brueckmann M. Long-term prognostic value of mid-regional pro-adrenomedullin and C-terminal pro-endothelin-1 in patients with acute myocardial infarction. Clinical Chemistry and Laboratory Medicine 2008 46 204-211. (doi:10.1515/CCLM.2008.040)
10. Kato J, Tsuruda T, Kita T, Kitamura K & Eto T. Adrenomedullin: a protective factor for blood vessels. Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 2480-2487. (doi:10.1161/01.ATV.0000184759.91369.f8)
11. Zudaire E, Cuttitta F & Martínez A. Regulation of pancreatic physiology by adrenomedullin and its binding protein. Regulatory Peptides 2003 112 121-130. (doi:10.1016/S0167-0115(03) 00030-2)
12. Li Y, Jiang C, Wang X, Zhang Y, Shibahara S & Takahashi K. Adrenomedullin is a novel adipokine: adrenomedullin in adipocytes and adipose tissues. Peptides 2007 28 1129-1143. (doi:10.1016/j.peptides.2007.03.005)
13. Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, Engström G, Persson M, Smith JG, Magnusson M, Christensson A, Struck J, Morgenthaler NG, Bergmann A, Pencina MJ & Wang TJ. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. Journal of the American Medical Association 2009 302 49-57. (doi:10.1001/jama. 2009.943)
14. Masson S, Latini R, Carbonieri E, Moretti L, Rossi MG, Ciricugno S, Milani V, Marchioli R, Struck J, Bergmann A, Maggioni AP, Tognoni G, Tavazzi L & GISSI-HF Investigators. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. European Journal of Heart Failure 2010 12 338-347. (doi:10.1093/eurjhf/hfp206)
15. Meisinger C, Rückert IM, Rathmann W, Döring A, Thorand B, Huth C, Kowall B & Koenig W. Retinol-binding protein 4 is associated with prediabetes in adults from the general population: the Cooperative Health Research in the region of Augsburg (KORA) F4 Study. Diabetes Care 2011 34 1648-1650. (doi:10.2337/dc11-0118)
16. Rathmann W, Strassburger K, Heier M, Holle R, Thorand B, Giani G, Peters A & Meisinger C. Incidence of type 2 diabetes in the older German population and the effect of clinical and lifestyle risk factors: KORA S4/F4 cohort study. Diabetic Medicine 2009 26 1212-1219. (doi:10.1111/j.1464-5491.2009.02863.x)
17. Rathmann W, Haastert B, Icks A, Löwel H, Meisinger C, Holle R & Giani G. High prevalence of undiagnosed diabetes mellitus in southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia 2003 46 182-189. (doi:10.1007/s00125-002-1025-0)
18. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM & Smith SC Jr. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009 2 1640-1645. (doi:10.1161/CIRCULATIONAHA.109.192644)
19. Rathmann W, Haastert B, Herder C, Hauner H, Koenig W, Meisinger C, Holle R & Giani G. Differential association of adiponectin with cardiovascular risk markers in men and women? The KORA survey. International Journal of Obesity 2007 31 770-776. (doi:10.1038/sj.ijo.0803471)
20. Papassotiriou J, Morgenthaler NG, Struck J, Alonso C & Bergmann A. Immunoluminometric assay for measurement of the C-terminal endothelin-1 precursor fragment in human plasma. Clinical Chemistry 2006 52 1144-1151. (doi:10.1373/clinchem.2005.065581)
21. Caruhel P, Mazier C, Kunde J, Morgenthaler NG & Darbouret B. Homogeneous time-resolved fluoroimmunoassay for the measurement of midregional proadrenomedullin in plasma on the fully automated system B.R.A.H.M.S KRYPTOR. Clinical Biochemistry 2009 42 725-728. (doi:10.1016/j.clinbiochem.2009.01.002)
22. Perassolo MS, Almeida JC, Steemburgo T, Dall'Alba V, de Mello VD, Zelmanovitz T, de Azevedo MJ & Gross JL. Endothelial dysfunction and serum fatty acid composition in patients with type 2 diabetes mellitus. Metabolism 2008 57 1167-1172. (doi:10.1016/j.metabol.2008.01.006)
23. Little PJ, Ivey ME & Osman N. Endothelin-1 actions on vascular smooth muscle cell functions as a target for the prevention of atherosclerosis. Current Vascular Pharmacology 2008 6 195-203. (doi:10.2174/157016108784911966)
24. Seligman BG, Biolo A, Polanczyk CA, Gross JL & Clausell N. Increased plasma levels of endothelin 1 and vonWillebrand factor in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2000 23 1395-1400. (doi:10.2337/ diacare.23.9.1395)
25. Gü vener N, Aytemir K, Aksöyek S & Gedik O. Plasma endothelin-1 levels in non-insulin dependent diabetes mellitus patients with macrovascular disease. Coronary Artery Disease 1997 8 253-258. (doi:10.1097/00019501-199705000-00001)
26. Hayashi M, Shimosawa T, Isaka M, Yamada S, Fujita R & Fujita T. Plasma adrenomedullin in diabetes. Lancet 1997 350 1449-1450. (doi:10.1016/S0140-6736(05)64211-0)
27. Kinoshita H, Kato K, Kuroki M, Nakamura S, Kitamura K, Hisanaga S, Fujimoto S & Eto T. Plasma adrenomedullin levels in patients with diabetes. Diabetes Care 2000 23 253-254. (doi:10.2337/diacare.23.2.253)
28. Ruzicska E, Toth M, Tulassay Z & Somogyi A. Adrenomedullin and diabetes mellitus. Diabetes/Metabolism Research and Reviews 2001 17 321-329. (doi:10.1002/dmrr.223)
29. Lim SC, Morgenthaler NG, Subramaniam T, Wu YS, Goh SK & Sum CF. The relationship between adrenomedullin, metabolic factors, and vascular function in individuals with type 2 diabetes. Diabetes Care 2007 30 1513-1519. (doi:10.2337/dc06-1899)
30. Juan CC, Chuang TY, Chang CL, Huang SW & Ho LT. Endothelin-1 regulates adiponectin gene expression and secretion in 3T3-L1 adipocytes via distinct signaling pathways. Endocrinology 2007 148 1835-1842. (doi:10.1210/en.2006-0654)
31. Herder C, Baumert J, Thorand B, Koenig W, de Jager W, Meisinger C, Illig T, Martin S & Kolb H. Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984-2002. Diabetologia 2006 49 921-929. (doi:10.1007/s00125-006-0190-y)
32. Simonson MS & Ismail-Beigi F. Endothelin-1 increases collagen accumulation in renal mesangial cells by stimulating a chemokine and cytokine autocrine signaling loop. Journal of Biological Chemistry 2011 286 11003-11008. (doi:10.1074/jbc.M110.190793)
33. Zarpelon AC, Pinto LG, Cunha TM, Vieira SM, Carregaro V, Souza GR, Silva JS, Ferreira SH, Cunha FQ & Verri WA Jr. Endothelin-1 induces neutrophil recruitment in adaptive inflammation via TNFa and CXCL1/CXCR2 in mice. Canadian Journal of Physiology and Pharmacology 2012 90 187-199. (doi:10.1139/y11-116)
34. Roden M, Vierhapper H, Liener K & Waldhäusl W. Endothelin-1-stimulated glucose production in vitro in the isolated perfused rat liver. Metabolism 1992 41 290-295. (doi:10.1016/0026-0495(92)90273-D)
35. Shemyakin A, Salehzadeh F, Esteves Duque-Guimaraes D, Böhm F, Rullman E, Gustafsson T, Pernow J & Krook A. Endothelin-1 reduces glucose uptake in human skeletal muscle in vivo and in vitro. Diabetes 2011 60 2061-2067. (doi:10.2337/db10-1281)
36. Maier C, Clodi M, Neuhold S, Resl M, Elhenicky M, Prager R, Moertl D, Strunk G, Luger A, Struck J, Pacher R & Hülsmann M. Endothelial markers may link kidney function to cardiovascular events in type 2 diabetes. Diabetes Care 2009 32 1890-1895. (doi:10.2337/dc08-2168)
37. Volpe M, Francia P, Tocci G, Rubattu S, Cangianiello S, Elena Rao MA, Trimarco B & Condorelli M. Prediction of long-term survival in chronic heart failure by multiple biomarker assessment: a 15-year prospective follow-up study. Clinical Cardiology 2010 33 700-707. (doi:10.1002/clc.20813)